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Abstract
Background: The choice between disease- modifying drugs (DMDs) for the treatment 
of multiple sclerosis (MS) becomes more often a shared decision between the patient 
and the neurologist and MS nurse. This study aimed to assess which DMD attributes 
are most important for the healthcare professionals in selecting a DMD for a patient. 
Subsequently, within this perspective, the neurologists’ and nurses’ perspectives were 
compared. Lastly, the healthcare professionals’ perspective was compared with the 
patients’ perspective to detect any differences that may need attention in the com-
munication about DMDs.
Design: A best- worst scaling (BWS) was conducted among 27 neurologists and 33 MS 
nurses treating patients with MS to determine the importance of 27 DMD attributes. 
These attributes were identified through three focus groups with MS patients in a 
previous study (N=19). Relative importance scores (RISs) were estimated for each at-
tribute. Multivariable linear regression analyses were used to compare the different 
perspectives.
Results: According to the neurologists and nurses, safety of the DMD was the most 
important DMD attribute in the treatment decision, closely followed by effect on dis-
ability progression, quality of life and relapse rate. Patients with MS agreed with the 
importance of the last three attributes, but valued safety significantly lower (b=−2.59,	
P<.001).
Conclusions: This study suggests that, overall, neurologists and nurses regard the 
same DMD attributes as important as MS patients with the notable exception of 
safety. This study provides valuable information for the development of interventions 
to support shared decision making and highlights which attributes of DMDs may need 
additional attention.
K E Y W O R D S
multiple sclerosis, best-worst scaling, healthcare professionals, disease-modifying drugs, shared 
decision making, patients
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1  | INTRODUCTION
Multiple sclerosis (MS) is a degenerative disease of the central nerv-
ous system causing physical and cognitive disabilities.1 The relapsing- 
remitting form of MS (RRMS) can be treated with disease- modifying 
drugs (DMDs) to reduce progression or even induce improvements. 
DMD treatment requires long- term administration with a minimum 
of missed doses. DMDs are classified as first- , second- or third- line 
treatments. First- line DMDs are used in patients with mild disease ac-
tivity. In case of high disease activity or intolerance to the side  effects, 
second- or third- line DMDs may be chosen. These DMDs have more 
favourable effectiveness rates but less favourable safety profiles.2,3 
Overall, thirteen DMDs are currently approved by the European 
Medicine Agency and the Food and Drug Administration.4,5 This vari-
ety in DMDs often provides MS patients with more than one accept-
able option for treatment.
Therefore, a choice between DMDs needs to be made, which is 
often difficult. Besides differences in effectiveness rates and safety 
profiles, the DMDs can differ in other characteristics, or attributes, 
such as mode of administration and side  effects. To make an optimal 
choice, the patient’s preferences for such attributes should be incor-
porated in the decision. In shared decision making, the patient makes 
the decision about the treatment together with the healthcare profes-
sional.6 The healthcare professional ensures the patient is informed 
about the best available treatment options and supports the patient 
in clarifying the advantages and disadvantages of each of the options. 
The patient communicates his or her values and preferences for these 
advantages and disadvantages, and deliberates with the healthcare 
professional, in this case a neurologist and/or an MS nurse, about the 
treatment options to reach a decision. Decision aids, which are specif-
ically designed to support shared decision making, have been shown 
to improve the patients’ involvement in the decision and the quality 
of the decision.7
Understanding the preferences of patients and healthcare pro-
fessionals for treatment options could inform the development of 
a decision aid. Although the treatment decision should be individu-
alized to every patient and should include the patient’s preferences 
and healthcare professional’s opinion tailored to the patient’s needs, 
the evaluation of the average perspectives about the importance of 
the treatment attributes in the decision could be useful for developing 
a patient decision aid that meets most patients’ and healthcare pro-
fessionals’ informational needs. An assessment of the average pref-
erences could be valuable for selecting the information that needs to 
be included in the decision aid to ensure effectively supporting the 
shared decision- making process without making the use of the deci-
sion aid too cognitively burdensome for the patient. Preferences of 
patients for attributes of DMDs have been evaluated in several stated 
preference studies.8-16 Recently, focus groups and a best- worst scal-
ing were conducted to identify and prioritize a range of attributes 
that could be important in clinical decision making from the patients’ 
perspective.8 This study found that the average MS patient regarded 
the effects on disability progression and quality of life as the most im-
portant attributes of DMDs in the decision, followed by the effect on 
the relapse rate, severity of side effects and the effect on the severity 
of relapses.8 Several studies showed that preferences of healthcare 
professionals for treatment options can differ from the preferences of 
patients.17-21 These differences in preferences could result in different 
expectations and information needed from the decision aid. In MS, 
one study has assessed the neurologists’ perspective regarding the im-
portance of a limited number of five attributes in the DMD choice.22 
To our knowledge, the patients’ perspective on important DMD at-
tributes for choosing between DMDs has not yet been directly com-
pared with the healthcare professionals’ perspective.
This study aimed first to use a rigorous method, a best- worst scal-
ing, to identify which DMD attributes the healthcare professionals 
(neurologists and MS nurses) find important to take into consideration 
in the decision regarding DMD treatment. As the relationship with the 
patient may differ between neurologists and MS nurses because of the 
more frequent and informal contact between MS nurses and patients, 
the second aim of this study was to evaluate whether the perspectives 
on the importance of DMD attributes differ between neurologists and 
MS nurses. Third, the overall MS healthcare professionals’ (neurolo-
gists and MS nurses) perspective was compared with the MS patients’ 
perspective on the importance of DMD attributes in the treatment 
decision.
2  | METHODS
A best- worst scaling case 1 as described by Flynn and Marley23 was 
conducted to obtain the neurologists’ and MS nurses’ perspective on 
the importance of attributes of DMDs. In contrast to discrete choice 
experiments, a best- worst scaling allows for obtaining the relative im-
portance of attributes for a large number of attributes, regardless of 
the levels of the attributes.24 The best- worst scaling was embedded 
Key points
• Understanding the healthcare professionals’ perspective 
about the importance of attributes of disease modifying 
drugs for multiple sclerosis, and comparing this perspec-
tive with the patients’ perspective, would be important to 
develop a patient decision aid that is accepted by, and 
usable for, both patients and healthcare professionals in 
the shared decision-making process
• The healthcare professionals and patients overall agree 
about the importance of the effects of DMDs on disabil-
ity progression, quality of life and relapse rate, but safety 
was valued significantly lower by patients.
• The study results provide guidance for the selection of 
information to be included in a patient decision aid for 
disease-modifying drugs in multiple sclerosis to effec-
tively support the patient and healthcare professional in 
making a shared decision.
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in an online questionnaire. Therefore, the Checklist for Reporting 
Results of Internet E- Surveys was followed for reporting the design 
and the results.25 We used the same best- worst scaling that was per-
formed to elicit preferences for patients with MS.8 The best- worst 
scaling included 27 attributes, which were identified in a two- stage 
procedure. First, in an exploratory phase, possible relevant attributes 
were identified through a literature review and interviews with three 
neurologists and three nurses. Second, three focus groups (N=19) 
were conducted to elicit the attributes that patients with MS regarded 
important in the decision. At the end of each focus group, any addi-
tional attributes from the exploratory phase that were not mentioned 
yet were discussed to evaluate whether these additional attributes 
were relevant as well. A total of 27 important attributes for the deci-
sion about DMD treatment were identified. Using Sawtooth SSI Web 
version 8.2.0, four best- worst scaling versions, each consisting of 17 
unique choice tasks with five attributes per choice task, were created 
to obtain the most efficient, fractional design. In such a design, it is 
not needed to include all possible combinations of attributes in the 
choice tasks, which is far too burdensome to administer. Instead, spe-
cific sets of five attributes from the full attribute lists are created to 
ensure that the relative importance of each attribute can be derived. 
Each attribute was presented 12 or 13 times in the four best- worst 
scaling version, was combined at least once with every other attribute 
and appeared two to four times in each position in the choice task. 
Each respondent randomly received one of the best- worst scaling ver-
sions. In every choice task, the respondent was asked to state which 
attributes were the most and the least important in the decision about 
DMDs, making a hypothetical trade- off between the attributes.24 
The best- worst scaling was pilot tested among researchers (n=3) and 
patients with MS (n=3) to ensure comprehensibility of the question-
naire. An example of a choice task for neurologists and MS nurses is 
presented in Figure 1. Further description on the identification, selec-
tion and definition of attributes and on the development of the choice 
tasks and the questionnaire is described in detail elsewhere.8
In addition to the best- worst scaling choice tasks, questions 
about demographical and professional characteristics were included. 
The respondents had to answer all questions to complete the ques-
tionnaire. At the end of the questionnaire, an optional open question 
provided the respondents the opportunity to report any important 
attributes in the decision about DMD treatment they missed in the 
choice tasks of the best- worst scaling.
2.1 | Subjects
Healthcare professionals were eligible for participation in the study 
if they were neurologists (i.e. MS- specialized neurologists or gen-
eral neurologists) or MS nurses (i.e. MS- specialized nurses or nurse 
practitioners, physician assistants or nurse consultants specialized 
in MS) and involved in the treatment of patients with MS in the 
Netherlands. These healthcare professionals generally work in hos-
pitals. The Netherlands counts about 80 (academic or general) hospi-
tals. The neurological department of a hospital generally consists of 
multiple neurologists of which some neurologists may have one or a 
few specific areas of focus. The exact number of MS neurologists in 
the Netherlands is unknown, but most departments have one, two or 
three neurologists who focus on the treatment of patients with MS. 
About 135 MS nurses were working in the Netherlands at the time of 
the study.
Neurologists with a focus on the treatment of MS were identified 
by searching websites of all hospitals in the Netherlands. We compiled 
a mailing list for 120 neurologists through the network of one of the au-
thors (PJ)—including the MS working group of the Dutch Neurologists 
Association and the MSmonitor Working Group—or through personal 
contact with the hospital. The neurologists were asked to participate 
through an email explaining the purpose of the study and containing a 
direct link to the online questionnaire. Additionally, an extra reminder 
email, in which the neurologists were personally addressed, was sent 
to 52 members of the MS Working Group of the Dutch association for 
neurology and the MSmonitor Working Group, of which six neurolo-
gists responded to have completed the questionnaire earlier and four 
neurologists responded to have completed the questionnaire after the 
email was sent.
Nurses were contacted through a call on the communication sys-
tem of the professional association for MS nurses to which about 
150 MS nurses and other nurses with an interest in MS had access 
and, additionally, through an email to 88 nurses to increase response. 
MS nurses for this mailing list were identified via an inventory of MS 
caregivers and healthcare institutions published on a patient infor-
mation website about MS endorsed by a Dutch patient association. 
Additionally, all nurse practitioners and physician assistants in MS 
(N=15) were also contacted through a mailing list of their professional 
association. In case of no response among the neurologists and nurses, 
a reminder email was sent after 1 and 2 weeks after the first email. 
The neurologists and nurses were informed that by completing the 
questionnaire they gave consent for their responses to be used in the 
study. Cookies were used to prevent the same respondent from filling 
out the questionnaire twice. The study was fully anonymous, and no 
data, such as IP addresses, were recorded that could lead to the iden-
tity of the healthcare professional.F I G U R E  1 Example of a choice task in the best- worst scaling
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2.2 | Analyses
Only completed questionnaires were included in the analyses. 
Descriptive statistics were used to present characteristics of the neu-
rologists and MS nurses. To evaluate the preferences of the healthcare 
professionals for the DMD attributes, Sawtooth SSI Web version 
8.2.0 was used to perform a hierarchical Bayes model employing 
a multinomial logit procedure.26 A raw score for the importance of 
each attribute was calculated in an iterative process of estimating 
each respondent’s utility score conditionally on estimates of other 
respondents’ utility scores. The raw score was rescaled to a relative 
importance score (RIS) on a ratio scale.27 The RIS of an attribute repre-
sents the importance of the attribute in relation to the importance of 
the other attributes in the decision about the DMD treatment of MS 
according to the professionals. The RISs of all 27 attributes for each 
respondent sum up to 100. Therefore, if there would be no difference 
in importance of the attributes, each attribute would obtain a RIS of 
3.7. Deviations from this score would suggest that some attributes are 
more important in the treatment decision than others. To ensure only 
responses of neurologists and MS nurses who answered the ques-
tions carefully were included in the analyses, respondents with a fit 
statistic (root likelihood) below .247 were omitted from the analyses 
as a fit statistic below this score would suggest random answers to the 
choice tasks.28 In addition to the RISs, most- minus- least counts were 
calculated to confirm the rankings of the attributes. To adjust for an 
imbalance in the number of times an attribute was shown to each re-
spondent in the best- worst scaling, the most- minus- least counts were 
divided by the frequency of each attribute being included in the ques-
tionnaire across the four versions.24
Multivariable linear regression analyses were conducted with 
SPSS for Windows version 24 to assess whether the RISs of the 27 
attributes differed between neurologists and MS nurses while con-
trolling for sex and three professional characteristics. Two charac-
teristics indicated the amount of experience in treating patients with 
MS: the number of years treating patients with MS dichotomized 
into	 ≤15	years	 or	 >15	years	 and	 the	 number	 of	 patients	with	MS	
treated	yearly	dichotomized	into	≤150	patients	per	year	or	>150	pa-
tients treated per year. The third characteristic denoted the extent 
to which the healthcare professional was specialized in treating pa-
tients with MS on a continuous scale and was defined as the number 
of patients with MS treated as proportion of the total number of 
patients treated.
To assess whether the RISs assigned by the neurologists and nurses 
to the 27 attributes differed from the RISs assigned by the patients with 
MS, hierarchical Bayes analyses were conducted including responses 
of the neurologists and nurses, and responses of patients obtained in a 
previous study.8 A second linear regression model was built to control 
for age, sex and level of education in the function between the respon-
dent type (i.e. healthcare professional or patient) and the RISs of the 27 
attributes. Level of education was dichotomized into respondents who 
had completed primary and/or secondary school only and respondents 
who had completed any additional type of tertiary education. The pa-
tients’ perspective was obtained from a previous study among 185 
patients with relapsing- remitting MS or clinically isolated syndrome, 
and with a range in experience with DMDs (from having never used a 
DMD to having used more than three different DMDs) and duration of 
diagnosis. Further detailed description of the patient recruitment and 
the patients characteristics can be found elsewhere.8
3  | RESULTS
Of the 120 neurologists and an estimated 140 nurses contacted, 
79 healthcare professionals accessed the questionnaire between 20 
November 2015 and 8 February 2016. In total, 62 healthcare pro-
fessionals completed the questionnaire (estimated overall completion 
rate of 24%), of which two healthcare professionals did not meet the 
inclusion criteria because they were working in Belgium (n=1) or did 
not treat patients with MS on a regular basis (n=1). The sample of 
60 healthcare professionals that met the inclusion criteria consisted 
of 27 (45%) neurologists and 33 (55%) nurses. Table 1 presents their 
characteristics. Twenty- four (89%) neurologists reported to be spe-
cialized in MS. Of the MS nurses, 23 (70%) MS- specialized nurses, one 
(3%) nurse consultant MS, seven (21%) nurse practitioners MS and 
two (6%) physician assistants MS completed the questionnaire. The 
median proportion of patients with MS expressed as a percentage of 
the total number of patients treated was 20% among neurologists and 
50% among nurses, of which eight nurses reported to only treat pa-
tients with MS.
As all fit statistics of the questionnaires were above .247 (mean 
.557; range .341, .769), indicating that none of the healthcare profes-
sionals answered the choice tasks completely at random, all completed 
questionnaires were included in the analyses. The ranking of the DMD 
attributes according to the mean RISs showed that healthcare profes-
sionals regarded safety, that is risks of life- threatening or severely dis-
abling adverse events, as most important (mean RIS [SD]: 9.29 [0.92]), 
but was followed closely by effect on disability progression, effect on 
quality of life and effect on relapse rate with only small differences 
between the RISs (mean RIS [SD]: 9.27 [1.58], 9.19 [0.83] and 8.89 
[0.88], respectively). Other highly ranked attributes were effect on de-
velopment of plaques in the brain (i.e. MS activity on MRI), severity of 
side effects and the effect on severity of relapses. Ten DMD attributes 
were of little or no importance in the decision for the healthcare pro-
fessionals with mean RIS below 1.0, including the required monitoring 
and administration frequency. The results of the adjusted most- minus- 
least counts (Table S1 Most- minus- least counts) did not substantially 
affect the rankings obtained based on the hierarchical Bayes analy-
ses and therefore confirmed the results. Of the 60 neurologists and 
nurses, two (3%) neurologists reported additional DMD attributes that 
were not included in the best- worst scaling: teratogenic properties of 
the DMD and the certainty of achieving the effects of the DMD.
3.1 | Comparison of neurologists with MS nurses
Only few differences were found between neurologists and nurses 
(Table 2). When comparing neurologists to nurses, relatively large 
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differences in mean RISs (absolute difference in RISs of 1 or more) 
were found in effect on current MS symptoms, effect on life expec-
tancy and total costs of the DMD, which were higher for the neu-
rologists, and interaction with other medication, which was higher 
for nurses. However, when controlling for sex, the years of work ex-
perience, the number of patients with MS treated each year and the 
degree of focus on MS treatment, only a significant difference was 
found between neurologists and nurses in the low ranked attributes 
total	cost	of	the	DMD	(b=−1.27,	P=.015) and interaction with other 
medication (b=2.09, P=.007). These differences resulted in quite sub-
stantial shifts in ranking: total cost of the DMD was ranked 17th by 
neurologists (RIS=1.22) and 25th by nurses (RIS=0.16), and interaction 
with other medication was ranked 18th by neurologists (RIS=1.10) 
and 13th by nurses (RIS=2.97). Based on their RISs though, these at-
tributes did not influence the treatment decision severely.
3.2 | Comparison of healthcare professionals 
(neurologists and MS nurses) with patients
When controlling for age, sex and level of education, there were sig-
nificant differences found between the RISs of the healthcare profes-
sionals and the patients with MS for six attributes at an alpha of .05: 
effect on relapse rate and safety were more important for neurolo-
gists and nurses, while effect on current MS symptoms, pace of effect, 
insurance coverage and further development of the DMD were more 
important for the patients in the decision about DMDs. Furthermore, 
while the difference in RIS of 1.01 between the health care 
professionals and patients for influence on lifestyle was quite sub-
stantial, this difference was not significant when controlling for age, 
sex and level of education (P=.063). For safety, the difference was 
the most notable: the RIS for patients was substantially lower than 
for	 neurologists	 and	 nurses	 (b=−2.59,	 P<.001), making safety the 
fourth most important attribute for neurologists and nurses, and 
only the eighth most important attribute for patients. Table 3 pre-
sents the results of the multivariable regression analyses for all 27 
attributes. Figure 2 presents the relative importance score of each 
attribute according to patients with MS and neurologists and MS 
nurses.
4  | DISCUSSION
In this study, a best- worst scaling was used to assess the neurologists’ 
and MS nurses’ perspectives on the importance of 27 DMD attributes 
in the decision about DMD treatments, which enabled comparison of 
the healthcare professionals’ perspective to the patients’ perspective. 
A best- worst scaling is a rigorous method for assessing preferences 
often used in healthcare research,29 but, to our knowledge, has not 
been used before to prioritize the information about treatment op-










Male 21 (35.0) 20 (74.1) 1 (3.0)
Female 39 (65.0) 7 (25.9) 32 (97.0)
Age (in years)
mean (SD) 47.6 (8.7) 49.7 (9.2) 45.9 (8.1)
Range 30- 64 35- 64 30- 59
Work function, N (%)
MS- specialized neurologist 24 (40) 24 (88.9) - 
General neurologist 3 (5.0) 3 (11.1) - 
MS nurse 23 (38.3) - 23 (69.7)
Nurse practitioner MS 7 (11.7) - 7 (21.2)
Physician assistant 2 (3.3) - 2 (6.1)
Nurse consultant 1 (1.7) - 1 (3.0)
Work experience in years, mean (SD)
≤15 45 (75.0) 16 (59.3) 29 (87.9)
>15 15 (25.0) 11(40.7) 4 (12.1)
Number of MS patients treated yearly, mean (SD)
≤150 24 (40.0) 11 (40.7) 13 (39.4)
>150 36 (60.0) 16 (59.3) 20 (60.6)
Proportion MS patients from total number of patients treated (in %)
Median (IQR) 40 (20- 67.5) 20 (10- 40) 50 (40- 95)
IQR, interquartile range; MS, multiple sclerosis; SD, standard deviation.
TABLE  1 Characteristics of the health 
care professionals
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This study found that neurologists and MS nurses ranked safety, 
effect on disability progression, effect on quality of life and effect on 
relapse rate highest. These attributes were thus considered as most 
influential in the decision making. Next in ranking were attributes 
focused on other effects and on side effects. Influence on lifestyle 
was the highest ranked (10th) attribute not directly related to bene-
fits and possible harms but was only awarded a mean RIS of almost 
half of the most important attribute. One other study has evaluated 
the neurologists’ perspective on important attributes in decisions 
about DMD by asking neurologists in the United States to rank five 
attributes. This study found, similarly to the current study, that ef-
ficacy and safety were the most important attributes, followed by 
tolerability, patient preferences and, lastly, convenience.22 Within 
the group of healthcare professionals, we expected some differences 
in importance of attributes between neurologists and nurses as a 
result of a difference in the relationship with the patient. However, 
in our study we found only statistical differences in two low ranked 
attributes, suggesting that neurologists and MS nurses do not dif-
fer much in their perspective about what to consider in the decision 
about DMDs.
TABLE  2 Relative importance scores of the DMD attributes in the treatment decision according to neurologists and nurses, and results of 
the multivariable analyses for work function (neurologist or nurse) while controlling for other variables
Attribute







Mean (SD) b [95% CI] t(59) p
Effect on disability progression 1 9.41 (1.78) 3 9.17 (1.41) −1.14	[−2.43.	0.16]	 −1.76 .084
Safety 2 9.19 (0.83) 1 9.38 (0.98) −0.03	[−0.77.	0.72]	 −0.07 .943
Effect on quality of life 3 9.02 (0.90) 2 9.34 (0.74) 0.58	[−0.09.	1.26]	 1.73 .089
Effect on relapse rate 4 8.98 (0.84) 4 8.81 (0.92) −0.03	[−0.77.	0.72]	 −1.61 .113
Effect on development of 
plaques in the brain
5 8.16 (1.23) 5 8.55 (1.66) 0.12	[−1.11.	1.34]	 0.19 .851
Severity of side effects 6 8.14 (1.20) 6 8.00 (0.92) −0.48	[−1.37.	0.40]	 −1.10 .276
Effect on the severity of relapse 7 7.08 (2.11) 7 7.52 (1.56) 0.41	[−1.10.	1.91]	 0.54 .590
Effect on current MS symptoms 8 6.45 (2.83) 9 5.13 (2.97) −0.40	[−2.74.	1.93]	 −0.35 .731
Effect on life expectancy 9 5.71 (3.19) 12 4.23 (3.07) −0.78	[−3.40.	1.84]	 −0.60 .554
Uncertainty about long- term 
consequences
10 5.63 (1.98) 11 4.72 (2.20) −1.34	[−3.09.	0.41]	 −1.53 .131
Influence on lifestyle 11 4.94 (0.61) 8 5.14 (0.59) 0.21	[−0.28.	0.71]	 0.86 .392
Type of side effects 12 4.65 (1.42) 10 4.79 (1.56) −0.09	[−1.27.	1.10]	 −0.14 .886
Duration of side effects 13 2.42 (1.07) 14 2.83 (1.72) 0.59	[−0.64.	1.82]	 0.97 .338
Pace of effect 14 2.02 (1.90) 15 2.83 (2.15) 0.74	[−0.92.	2.41]	 0.90 .374
Mode of administration 15 1.50 (1.60) 16 1.26 (1.22) −0.73	[−1.90.	0.43]	 −1.26 .213
Insurance coverage 16 1.37 (2.60) 18 1.04 (1.97) −0.28	[−2.17.	1.62]	 −0.29 .771
Total DMD costs 17 1.22 (1.80) 25 0.16 (0.26) −1.27	[−2.29.	−0.25]* −2.50 .015
Interaction with other 
medication
18 1.10 (0.83) 13 2.97 (2.32) 2.09 [0.60. 3.59]* 2.81 .007
Required monitoring 19 0.78 (1.01) 19 0.92 (1.59) 0.79	[−0.24.	1.81]	 1.54 .129
Mode of action of DMD 20 0.67 (1.44) 17 1.17 (1.82) 0.75	[−0.55.	2.05]	 1.15 .254
Frequency of administration 21 0.66 (0.62) 20 0.85 (0.70) 0.19	[−0.36.	0.74]	 0.70 .488
Duration of administration 22 0.35 (0.35) 24 0.17 (0.14) −0.05	[−0.25.	0.14]	 −0.55 .586
Further development of DMD 23 0.25 (0.64) 21 0.43 (0.65) 0.26	[−0.26.	0.78]	 1.01 .316
Use of DMD among other MS 
patients
24 0.11 (0.10) 23 0.20 (0.17) 0.10	[−0.02.	0.21]	 1.61 .114
Ease of travelling 25 0.10 (0.32) 26 0.09 (0.09) 0.05	[−0.14.	0.23]	 0.53 .598
Composition of DMD 26 0.08 (0.14) 22 0.29 (0.51) 0.29	[−0.04.	0.61]	 1.77 .082
Contact person at pharmaceu-
tical company
27 0.01 (0.03) 27 0.02 (0.04) −0.01	[−0.03.	0.02]	 −0.48 .634
CI, confidence interval; DMD, disease- modifying drug; MS, multiple sclerosis; RIS, relative importance score; SD, standard deviation.
*P<.05.
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The healthcare professionals and the patients both valued effect 
on disease progression, quality of life and relapse rate highly, which 
is not unexpected because these are the primary aims of DMD treat-
ment. The most notable difference between the two perspectives was 
found in the importance of safety. The healthcare professionals gave 
significantly more value to this attribute compared with patients. More 
specifically, safety was ranked as fourth most important by healthcare 
professionals, while ranked only eighth by patients, who gave more 
value to other attributes focused on effectiveness and the severity 
of more common side effects. In the process of shared decision mak-
ing, this could be an issue. Healthcare professionals may, for example, 
be less inclined than patients to choose a DMD for which experience 
and research has shown risks for life- threatening or severely disabling 
side effects, such as progressive multifocal leukoencephalopathy. 
TABLE  3 Relative importance scores of the DMD attributes in the treatment decision according to respondent type (i.e. neurologists/nurses 
or MS patients), and results of the multivariable analyses for respondent type while controlling for other variables
Attribute
Neurologists and nurses MS patients
Difference in RIS according to respondent 








mean (SD) b [95% CI] t(244) P
Effect on disability progression 1 9.50 (1.31) 1 9.64 (1.16) 0.19	[−0.20,	0.57] 0.96 .336
Effect on quality of life 2 9.23 (0.97) 2 9.21 (1.45) 0.07	[−0.36,	0.50] 0.31 .755
Effect on relapse rate 3 8.71 (1.31) 3 7.76 (2.58) −0.88	[−1.62,	−0.13]* −2.32 .021
Safety 4 8.69 (1.80) 8 6.04 (2.95) −2.59	[−3.45,	−1.72]* −5.90 <.001
Effect on development of 
plaques in the brain
5 8.00 (1.83) 7 7.31 (2.52) −0.49	[−1.24,	0.27] −1.27 .204
Severity of side effects 6 7.87 (1.09) 4 7.63 (2.11) −0.32	[−0.93,	0.29] −1.02 .307
Effect on the severity of 
relapse
7 7.51 (1.75) 5 7.39 (2.32) −0.08	[−0.77,	0.61] −0.23 .822
Effect on current MS 
symptoms
8 6.28 (2.52) 6 7.32 (1.97) 1.13 [0.46, 1.81]* 3.31 .001
Uncertainty about long- term 
consequences
9 5.45 (2.31) 12 4.58 (2.76) −0.82	[−1.66,	0.03] −1.91 .057
Effect on life expectancy 10 4.97 (3.07) 11 4.81 (3.13) 0.11	[−0.87,	1.10] 0.23 .818
Type of side effects 11 4.70 (1.81) 10 5.00 (2.71) 0.07	[−0.73,	0.87] 0.17 .863
Influence on lifestyle 12 4.30 (2.68) 9 5.31 (2.92) 0.86	[−0.05,	1.77] 1.87 .063
Duration of side effects 13 3.43 (1.44) 13 3.74 (1.97) 0.19	[−0.40,	0.79] 0.64 .521
Pace of effect 14 2.51 (2.00) 14 3.18 (2.19) 0.73 [0.04, 1.42]* 2.09 .038
Interaction with other 
medication
15 1.88 (1.76) 16 1.72 (1.86) 0.00	[−0.57,	0.56] −0.01 .992
Insurance coverage 16 1.47 (2.34) 15 2.71 (2.87) 1.05 [0.17, 1.93]* 2.34 .020
Mode of administration 17 1.37 (1.78) 17 1.58 (2.69) 0.00	[−0.80,	0.79] 0.00 .997
Mode of action of DMD 18 0.87 (1.44) 18 0.99 (1.25) 0.17	[−0.24,	0.57] 0.80 .422
Required monitoring 19 0.77 (1.27) 22 0.55 (1.18) −0.22	[−0.60,	0.17] −1.12 .264
Frequency of administration 20 0.71 (0.67) 21 0.68 (1.38) −0.13	[−0.53,	0.27] −0.65 .518
Total DMD costs 21 0.54 (1.05) 20 0.86 (1.27) 0.24	[−0.15,	0.63] 1.21 .226
Further development of DMD 22 0.44 (0.69) 19 0.87 (0.94) 0.49 [0.22, 0.77]* 3.49 .001
Duration of administration 23 0.23 (0.21) 25 0.20 (0.24) −0.02	[−0.09,	0.05] −0.50 .615
Composition of DMD 24 0.20 (0.41) 26 0.18 (0.36) −0.04	[−0.16,	0.08] −0.59 .553
Use of DMD among other MS 
patients
25 0.19 (0.21) 23 0.34 (0.56) 0.14	[−0.02,	0.29] 1.68 .095
Ease of travelling 26 0.14 (0.45) 24 0.29 (0.87) 0.08	[−0.18,	0.33] 0.60 .552
Contact person at pharmaceu-
tical company
27 0.03 (0.05) 27 0.10 (0.28) 0.06	[−0.02,	0.14] 1.47 .142
CI, confidence interval; DMD, disease- modifying drug; MS, multiple sclerosis; RIS, relative importance score; SD, standard deviation.
*P<.05.
178  |     KREMER Et al.
Motivations of patients, neurologists and nurses for the importance 
of the attributes were not elicited in the questionnaire; therefore, we 
can only speculate about the reasons for the difference found in the 
importance of the attributes, in particularly safety. A first explanation 
for the difference in the importance of safety might be that healthcare 
professionals have a different understanding of the seriousness of the 
risks and consequences than patients. Second, patients might be will-
ing to take more risk, as a previous study showed that patients were 
willing to accept larger risks than the risks associated with the DMDs 
available at that time, in exchange for effectiveness in reducing relapse 
rate and disability progression.9 Healthcare professionals may be less 
inclined to take these risks, for example, because of forensic and legal 
liability in case of incidents of serious adverse events.
This study shows which attributes are most important in the de-
cision, and that the rankings of the attributes are overall quite similar 
for neurologists, MS nurses and MS patients, with the exception of a 
few attributes—especially safety. It should be noted that the rankings 
reflect the average preferences. Therefore, the discrepancies do not 
necessarily play a role in every consultation. However, incorporating 
the patient’s preferences in the decision is an essential part of reaching 
a shared decision, which may be complicated if the healthcare profes-
sional and patient do not agree on the importance of some attributes 
in the decision. Patient decision aids can, besides provide information, 
also support the patient and the healthcare professional in eliciting 
and discussing the patient’s preferences.30 The results of this study 
contribute to the development of an MS decision aid by indicating the 
attributes—those attributes that both patients and healthcare profes-
sionals find most important and those attributes that are substantially 
more important for either patients or healthcare professionals—about 
which information and preference elicitation questions should be in-
cluded in the decision aid to enable effective support for reaching a 
shared decision. Moreover, this study shows that a best- worst scaling 
could be a useful tool in the future development of other interventions 
for supporting shared decision making, such as patient decision aids. In 
particular when there is a risk of developing overly cognitive burden-
some tools, a best- worst scaling may be useful in selecting the most 
essential attributes.
Some limitations of this study need to be considered. Only an 
estimated 24% of the contacted healthcare professionals completed 
the questionnaire. Possibly, more healthcare professionals with a 
more positive attitude towards research responded because of our 
recruitment methods. Therefore, the sample might not perfectly rep-
resent all MS neurologists and MS nurses in the Netherlands because 
they may have been better informed about the latest DMD devel-
opments, and they might have had different preferences for DMD 
attributes accordingly. Another limitation could be the small sample 
size, but the number of eligible healthcare professionals for this study 
is also limited. The Netherlands counts about 80 hospitals of which 
F IGURE  2 Relative importance scores of attributes of disease- modifying drugs according to neurologists, nurses and patients with multiple 
sclerosis
0 1 2 3 4 5 6 7 8 9 10
Contact person at pharmaceutical company
Composition of DMD
Ease of travelling
Use of DMD among other MS patients
Further development of DMD
Duration of administration
Frequency of administration
Mode of action of DMD
Required monitoring





Duration of side effects
Type of side effects
Influence on lifestyle
Uncertainty about long-term consequences
Effect on life expectancy
Effect on current MS symptoms
Effect on the severity of relapse
Severity of side effects
Effect on development of plaques in the brain
Effect on relapse rate
Effect on quality of life
Safety





     |  179KREMER Et al.
most hospitals have one, two or three neurologists with a focus on 
MS and one or two MS nurses, and we made efforts to invite all of 
them to participate. The sample size limited the ability to conduct a 
latent class analysis. In future research, evaluation of heterogeneity in 
preferences using latent class analysis could potentially provide more 
insight into groups of healthcare professionals with similar prefer-
ences. Furthermore, to compare the perspectives of the neurologists 
and the MS nurses with those of the patients, the best- worst scaling 
for both parties included the same attributes. These attributes were, 
however, identified through focus groups among patients only, and 
may not be the same attributes that the neurologists and MS nurses 
would have reported if focus groups among them would have been 
performed. Nevertheless, only two neurologists reported other attri-
butes that were not included in the best- worst scaling—teratogenic 
properties and uncertainty whether effects would be achieved—to be 
of importance as well. Another limitation is that it was necessary to 
ask different questions in the best- worst scaling for healthcare pro-
fessionals compared with the patients. Both groups were asked to 
choose the most and least important attribute for decision making, 
but patients were expected to answer this question according to their 
individual situation, while healthcare professionals were asked to an-
swer the question for patients with MS in general. This difference in 
framing of the question may have led to differences in what is re-
garded as important in the decision. Additionally, because of small de-
viations from normality of the residuals and homoscedasticity found 
in the regression analyses, generalization of the found differences in 
total costs of the DMD and interaction with other medication be-
tween neurologists and nurses and the differences in effect on re-
lapse rate, insurance coverage, and further development of the DMD 
between the healthcare professionals and the patients beyond our 
sample should be done with caution. Lastly, it is uncertain whether 
our results may be transferred to other settings as the healthcare sys-
tems in other settings may differ. Therefore, some attributes, such as 
DMD costs, may be more important for the decision in other settings. 
Other limitations that apply to the best- worst scaling method and the 
results of the patients’ perspective have been reported elsewhere.8
5  | CONCLUSION
This study showed that safety, effect on disability progression and 
effect on quality of life were the most influential attributes of DMDs 
for healthcare professionals in the treatment decision. The impor-
tance of these and other highly ranked attributes did not differ be-
tween neurologists and nurses when making a decision for patients 
with MS in general. Additionally, the average healthcare professionals’ 
perspective and the average patients’ perspective agree that the abil-
ity of DMDs to reduce disability progression and maintain or improve 
quality of life are the most important attributes of a DMD. The per-
spectives differ however considerably about the importance of safety. 
These results provide valuable information for the development of in-
terventions to support shared decision making. This study also dem-
onstrates the feasibility of combining focus groups and a best- worst 
scaling to identify important attributes that could later be included 
in a patient decision aid. A best- worst scaling could be an interesting 
method when having to restrict the number of attributes for inclusion 
in a patient decision aid.
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